Assessment of liver function in patients with type 2 diabetes receiving ertugliflozin

被引：0
|
作者：
Gallo, S. [1 ]
Calle, R. A. [2 ]
Terra, S. G. [3 ]
Pong, A. [4 ]
Tarasenko, L. [5 ]
Raji, A. [4 ]
机构：
[1] Pfizer Pharma GmbH, Berlin, Germany
[2] Pfizer Inc, Cambridge, MA USA
[3] Pfizer Inc, Andover, MA USA
[4] Merck & Co Inc, Kenilworth, NJ USA
[5] Pfizer Inc, New York, NY USA
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
712
引用
收藏
页码：S341 / S341
页数：1
相关论文
共 50 条
  • [21] Ertugliflozin in type 2 diabetes: a profile of its use
    Lesley J. Scott
    [J]. Drugs & Therapy Perspectives, 2019, 35 : 351 - 362
  • [22] Effect of canagliflozin on liver function tests in patients with type 2 diabetes
    Leiter, L. A.
    Forst, T.
    Polidori, D.
    Balis, D. A.
    Xie, J.
    Sha, S.
    [J]. DIABETES & METABOLISM, 2016, 42 (01) : 25 - 32
  • [23] Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus
    Liu, Jie
    Patel, Shrita
    Cater, Nilo B.
    Wu, Larry
    Huyck, Susan
    Terra, Steven G.
    Hickman, Anne
    Darekar, Amanda
    Pong, Annpey
    Gantz, Ira
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (04): : 574 - 582
  • [24] Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
    Fediuk, Daryl J.
    Zhou, Susan
    Dawra, Vikas Kumar
    Sahasrabudhe, Vaishali
    Sweeney, Kevin
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (07): : 696 - 706
  • [25] Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus
    Liu, Jie
    Tarasenko, Lisa
    Pong, Annpey
    Huyck, Susan
    Wu, Larry
    Patel, Shrita
    Hickman, Anne
    Mancuso, James P.
    Gantz, Ira
    Terra, Steven G.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (08) : 1277 - 1284
  • [26] Evaluation of Fractures, Bone Mineral Density (BMD), and Bone Biomarkers in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin
    Hickman, Mary A.
    Frederich, Robert
    Patel, Shrita M.
    Gallo, Silvina
    Lauring, Brett
    Terra, Steven
    Johnson, Susan L.
    Masiukiewicz, Urszula
    Huyck, Susan
    Mancuso, James P.
    [J]. DIABETES, 2018, 67
  • [27] Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phaseIIIstudies
    Pratley, Richard
    Charbonnel, Bernard
    Patel, Shrita
    Hickman, Anne
    Liu, Jie
    Tarasenko, Lisa
    Pong, Annpey
    Ellison, Misoo C.
    Huyck, Susan
    Gantz, Ira
    Terra, Steven G.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (12): : 2276 - 2286
  • [28] COST EFFECTIVENESS OF EMPAGLIFLOZIN VS. ERTUGLIFLOZIN IN PATIENTS WITH TYPE-2 DIABETES
    Supner, P.
    Park, T.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S367 - S368
  • [29] Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
    Silvina Gallo
    Roberto A. Calle
    Steven G. Terra
    Annpey Pong
    Lisa Tarasenko
    Annaswamy Raji
    [J]. Diabetes Therapy, 2020, 11 : 1849 - 1860
  • [30] Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
    Gallo, Silvina
    Calle, Roberto A.
    Terra, Steven G.
    Pong, Annpey
    Tarasenko, Lisa
    Raji, Annaswamy
    [J]. DIABETES THERAPY, 2020, 11 (08) : 1849 - 1860
12345